Meta Pixel
Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

News and Announcements

Positive Interim Phase 2 Trial Results for CAVATAK™, Novel Cancer Immunotherapy

  • Published April 08, 2014 10:22AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

To read the full ASX Media Release please download the document below.

Join over 45,000+ sophisticated investors

Join Now